Heparin shows blood pressure lowering effect in hypertensive patients and animal models. The present study examined the effect of heparin on vasoconstrictor endothelin-1 (ET-1) production in cultured human umbilical vein endothelial cells (ECs) to elucidate the mechanism of antihypertensive effect of heparin. Heparin suppressed both basal and thrombin-stimulated ET-1 mRNA expression paralleled with a decrease in ET-1 peptide release in a dose-dependent manner. Heparin concomitantly enhanced nitric oxide (NO) formation measured by N02/ NO3 levels and cGMP production in ECs. These enhancements were more marked when ECs were stimulated by thrombin. However, these heparin's effects were blunted in the presence of endothelium-derived nitric oxide (EDNO) synthesizing inhibitor NG-monomethyl L-arginine. Therefore, these results suggest that suppression of ET-1 production by heparin is EDNO
Introduction
Heparin, which is widely used as an anticoagulant, given chronically shows a blood pressure-lowering effect in hypertensive patients ( 1, 2) and animal models (3) (4) (5) . This antihypertensive effect is accompanied by a profound fall in total peripheral resistance (6) . However, the physiological role of circulating heparin remains in question.
Endothelin-1 (ET-1 ), ' identified (7) as a product of vascular endothelial cells (ECs), exerts potent vasoconstrictor and vascular smooth muscle cell (VSMC) proliferative actions (8) . Elevated levels of this peptide have been reported in patients with acute myocardial infaction (9) , acute renal failure (10) , or severe hypertension ( 1 1, 12) . On the other hand, endothe-lium-derived nitric oxide (EDNO), which is also released from vascular ECs, exerts vasodilator action in humans ( 13) and is thought to function as a modulator of VSMC mitogenesis and proliferation by a cGMP-mediated mechanism (14) . Thrombin stimulates the production of both ET-l and EDNO (15) . EDNO released during stimulation with thrombin inhibits the production of ET-I via a cGMP-dependent pathway in aortic ECs ( 15) .
Recently, we have shown that bolus administration ofET-I to heparin-treated (4 wk) spontaneously hypertensive rats (SHR) showed an exaggerated initial depressor response and a blunted pressor response compared to those in control SHR. In addition, heparin effectively suppressed ET-1 release from cultured rat ECs ( 16) . These findings have led us to hypothesize that heparin's antihypertensive effect is EDNO mediated.
This study was designed to examine whether heparin affects ET-I production in human ECs; and if this effect is influenced by EDNO inhibitor N -monomethyl L-arginine (LNMMA), in order to further elucidate the heparin's antihypertensive mechanism. It is critical that we reevaluate the mechanism of action of heparin in human endothelial cells for its potential application in clinical use.
Methods
Cell culture. Human ECs were obtained from umbilical veins according to the method described previously ( 17) . Cells were grown in medium-199 (Gibco BRL, Grand Island NY) supplemented with 5% (vol/vol) FCS, endothelial cell growth supplement (ECGS) at 50 mg/ ml (Sigma Chemical Co., St. Louis, MO.), penicillin (50 jU/ml), and streptomycin (50 jg/ml). EC purity was assessed by phase contrast microscopy involving a detection of a characteristic "cobblestone appearance" and by immunofluorescence staining with a Factor VIII antiserum. VSMC contamination was less than 0.1%. The cultured ECs had three to five passages before being used in this study. When cells were confluent, the medium was replaced and incubated with fresh medium-199 without serum and ECGS for 24 h before the experiments. After removal ofthe culture medium, ECs were incubated with several agents, including heparin derived from bovine lung and having its Activity at 140 USP U/mg, and thrombin (both from Sigma Chemical Co.), and LNMMA (Calbiochem Corp., San Diego, CA.), or these agents in combination, in serum-free medium-199 without ECGS.
Extraction andRIA ofET-1. ET-1 was extracted from 4-ml-culture medium through a Sep-Pak C18 cartridge (Waters Chromatography Div., Millipore Corp., Milford, MA) by the method described previously ( 1). The ET-1 concentration in the medium was measured by radioimmunoassay with the use of antibody against ET-1 (Peninsula Lab. Inc., Belmont, CA) and '251-labeled ET-1 (Amersham Japan Co., Tokyo) as a tracer. RNA isolation. Total RNA from cultured human umbilical vein ECs were extracted by the guanidinium-thiocyanate-phenol-chloroform method (18) . In brief, the cells were scraped and homogenized with 2 ml of solution buffer (4 M guanidium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, and 0.1 M 2-mercaptoethanol) and subsequently transferred to a polypropylene tube. Sequentially, 0.2 ml of 2 M sodium acetate, 2 ml phenol (water saturated), and 0.4 ml of chloroform-isoamyl alcohol mixture (49:1 ) were added to the homogenate, with thorough mixing by inversion. The final suspension was shaken vigorously for 10 sec and cooled on ice for 15 min. Samples were centrifuged at 10,000 g for 20 min at4VC. After centrifugation, RNA in the aqueous phase was transferred to a fresh tube, mixed with 2 ml of isopropanol, and then placed at -20'C for at least 2 h to precipitate RNA. Sedimentation at10,000 g for 20 min was again performed and the resulting RNA pellet was resuspended in 75% ethanol, sedimented, vacuum dried, and used as total RNA.
Northern blot analysisforET-I mRNA. Total RNA was denatured with 6% formaldehyde, fractionated by1% agarose gel electrophoresis, and transferred to a nylon membrane (Hybond-N; Amersham Japan). The membranes were prehybridized at 420C for 5 h in a buffer containing 50% formamide, 5X Denhardt's reagent, 10% Dextran sulfate, 5X
saline EDTA, and 100 Ag/ml denatured single strand DNA, and then hybridized with 32P-labeled 1.2 kb EcoRI fragment of human preproendothelin-I cDNA probes (20) in the same buffer at 420C for 16 h. After washing the filters, the hybridized RNA was visualized by exposure to Hyperfilm-TM (Amersham Japan) at -70'C. The membrane was prehybridized, hybridized, and washed as the Northern blot. The membranes were reprobed with a human #l-actin cDNA. The probe was labeled with [a-32P]dCTP by the multiprime DNA labeling system (Amersham Japan). After exposure to film, the probe was stripped by incubation in a buffer containing 5 mM Tris-HCI, pH 8.0, 2 mM EDTA, and 0.1 x Denhardt's reagent at 70°C for I h. The results were quantitated using a laser densitometer(Pharmacia LKB Biotechnology AB, Uppsala, Sweden).
Measurement of cGMP levels. Confluent ECs cultured in 6-well plates were preincubated for 15 min at 37°C in 1.4 ml of incubation buffer having the following composition (mM): 137 NaCl, 2.7 KCI, 8 Na2HPO4, 1.5 KH2PO4, 0.5 CaC12, 0.5 MgCl2, 3-isobutyl-1-methylxanthine 1, and 0.01 indomethacin. The incubation was started by adding 100 Al of solution (including heparin, thrombin, LNMMA, or these items in combination) and was stopped by adding 25 Al ofHC1 (1 N) after 30-min incubation according to the method previously published ( 17) . 1 h later, the buffer was then removed and neutralized with 25 AI of NaOH (1 N), and cGMP was measured by RIA using a cGMP assay kit (Yamasa Shoyu Co. Ltd., Chiba, Japan).
Nitrite (NO0/nitrate (NO_) assay. Cultured cells were assayed for NO synthesis by measuring the stable end product of NO, NO2, and NO3, as described by Bartholomew (21 ) and Granger et al. (22) . The cells were cultured in standard cultured flasks (5-7 X 10' cells) and incubated with several agents including heparin, thrombin, LNMMA, or these agents in combination in Dulbecco's PBS (D-PBS) with 70 mg/liter ofL-arginine hydrochloride for 2 h. After incubation, the medium was removed and cells were rinsed three times with PBS, followed by scraping cell layers into cold PBS. Homogenates were obtained by drawing the cell suspension through 25-gauge needles three times on ice. Samples were first incubated with Escherichia coli nitrate reductase to convert the NO3 in the samples to NO2 (23) for 90 min at 37°C, as reported previously (22) . After incubation, the total NO2 in the samples were measured using Greiss reagents as reported by Green et al. (24) . Absorbance was measured at 543 nm by spectrophotometer. Known concentration ofNaNO2 and NaNO3 were used as standards in each assay.
Calculation and statistical analysis. The statistical significance of the results was evaluated by ANOVA and P values were determined by the Student's t test.
Results
Effects of heparin on immunoreactive ET-J release from cultured human ECs. We assayed the release of ET-l by measuring immunoreactive ET-1 level in the medium of human ECs culture in the presence or absence ofheparin (Fig. 1 ) . Immunoreactive ET-1 was released from cultured human ECs in a timedependent manner. Thrombin (10 U/ml) enhanced ET-l release. Addition of heparin at a dose of 10 U/ml significantly decreased both basal and thrombin-stimulated ET-l levels in the medium. In our preliminary study heparin did not interfere with our assay of ET-1.
Effect ofheparin on ET-I mRNA expression. As shown in Fig. 2 , heparin ( 1-50 U/ml) suppressed both basal and thrombin (10 U/ml)-stimulated ET-1 mRNA expression in cultured human ECs in a dose-dependent fashion. We compared ET-1 mRNA expression between 1-and 4-h incubation periods (Fig. 3) . ET-1 mRNA increased more in 4-h incubation than that in 1-h incubation. However, heparin ( suggest that heparin regulates the transcription rates of ET-l mRNA expression in cells incubated with thrombin or vehicle.
Effect of heparin on cGMP production in the presence or absence of LNMMA. As shown in Fig. 4 , heparin enhanced basal and thrombin-stimulated cGMP production by cultured human ECs without serum in a dose-dependent manner. cGMP production was more marked in the presence ofthrombin ( 10 U/ml) than in its absence. On the other hand, in the presence of EDNO inhibitor LNMMA ( 1O -M), heparin had no effect on either basal or thrombin-stimulated cGMP level (Table II) . However, basal level of cGMP was not affected by LNMMA, similarly observed by other investigators ( 15 ) .
Effect of heparin on ET-J production in the presence of LNMMA. Like cGMP, heparin showed no effect on either basal or thrombin-stimulated ET-1 peptide release into the medium in the presence of LNMMA ( 10-M), although heparin suppressed both basal and thrombin-stimulated ET-1 release without LNMMA (Table III) . Similarly, the suppressive effect of heparin on basal and thrombin-stimulated ET-I mRNA expression was not observed in the presence of LNMMA at 10-5 M (Fig. 5 ).
:::... Effect ofheparin on the production ofNO2/NO3 in cultured human ECs. As shown in Table IV , heparin induced the production of N02/N03 in cultured human ECs in a dose-dependent manner. Heparin (10 U/ml) also enhanced thrombin ( 10 U/ml)-induced N02/N03 production. In the presence of LNMMA ( 10-5 M), heparin, thrombin, and a combination of both did not affect the production of N02/N03.
Discussion
Heparin is a widely used anticoagulant drug. Besides, heparin treatment has shown to cause blood pressure reduction in hypertensive humans (1) and rats (3) (4) (5) 16) . Thrombin is a potent agonist of ET-1 production by cultured human ECs. We have confirmed that thrombin stimulates ET-1 production, and have presented data showing that heparin strongly suppresses both basal and thrombin-stimulated ET-l mRNA expression and ET-1 peptide release. It has been reported that ECs do not contain a storage pool of ET-1; secretion of EC ET-1 is regulated primarily at the level of transcription (25) . The ET-l production is regulated by phosphoinositide turnover (25) . Heparin selectively inhibits a protein kinase C-dependent mitogenesis, changes in cellular morphology and proto-oncogene induction (26) . The ET-1 mRNA expression in cultured human ECs was found to be suppressed by heparin, corresponding to a decrease in ET-1 peptide level in the medium. These findings, together with those of AD experiments, indicate that heparin inhibits ET-l production, probably at the transcriptional level. However, the effect of heparin on transla-E E ----E.
-: = o .o , . Thrombin stimulates not only the production of the endothelin group, but also the production of vasodilator EDNO in a variety ofblood vessels (27, 28) . EDNO production can be inhibited stereospecifically by LNMMA, which is a false substrate for the enzyme synthesizing nitric oxide (29, 30) . Nitric oxide activates soluble guanylate cyclase and in turn increases cGMP level in ECs and VSMCs (31) (32) (33) . We have shown that both thrombin and heparin stimulate NO formation measured by N02/NO3 levels and cGMP production, and a combination of both markedly enhances the NO formation and the cGMP production. However, these heparins' stimulatory effect on NO formation and cGMP production were abolished in the presence of LNMMA, suggesting that heparin stimulates cGMP through EDNO-mediated pathway. Furthermore, in the presence of LNMMA, heparin did not affect either basal or thrombin-stimulated ET-1 mRNA expression and ET-1 peptide release. Therefore, these results suggest that heparin suppresses ET-1 production through an EDNO-cGMP mediated pathway. Heparin shows a potent anticoagulant action through inactivation of thrombin by activating antithrombin III in a serum (34) or by direct interaction with anion-binding exosite ofthrombin (35) . This study has been done under a serum-free condition, and furthermore, heparin enhanced thrombin-induced cGMP production and did not suppress ET-1 production in the presence of LNMMA. These findings indicate that suppression of ET-1 production is not due to the inactivation of thrombin by heparin.
In conclusion, our study provides a novel finding that heparin stimulates cGMP production in cultured human ECs, and subsequently suppresses the ET-1 production, probably at the transcriptional level through an EDNO-mediated pathway. Furthermore, heparin also enhances thrombin-stimulated cGMP production in cultured ECs without serum, and suppresses thrombin-induced ET-I production through the activation of an EDNO-mediated pathway. Taken together, it may be prudent to state that heparin regulates vascular tone through a combination of enhancement of EDNO and suppression of ET-1 production in human ECs.
